King of pain
12 October 2010
Email
Share
The drug group faces a big top line hit when its biggest seller goes offpatent next year. Buying pain specialist King Pharmaceuticals should offset some of the lost sales. Better yet, the value of promised synergies should more than cover the $1 bln premium Pfizer is paying.